ArticleResearch and practice in thrombosis and haemostasis2026
Heavy menstrual bleeding in women with a bleeding disorder of unknown cause: a common symptom impacting daily life functioning.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persons with an increased bleeding tendency without abnormalities in standard hemostasis tests are classified as having a bleeding disorder of unknown cause (BDUC). The majority are female, and the most common bleeding symptoms are mucocutaneous, including heavy menstrual bleeding (HMB). However, knowledge on HMB in BDUC and the impact on daily functioning is limited. Objectives: Investigate the prevalence of HMB and HMB-related quality of life (QoL) in women with BDUC, compared with women with mild bleeding disorders (MBDs) and no bleeding disorder (NBD). Methods: Data from women included in the Maastricht Predictors of Bleeding Evaluation in Adult Hematologic Patients with Bleeding Tendencies study were used. HMB was defined as a score ≥1 on the menorrhagia subdomain of the International Society on Thrombosis and Hemostasis Bleeding Assessment Tool. HMB-related QoL was evaluated using the Menorrhagia Multi-Attribute Scale (MMAS). Results: In total, 317 women were included (BDUC Conclusion: HMB is highly prevalent among women with BDUC, and HMB substantially impairs HMB-related QoL. This underscores the need for increased clinical awareness of the impact of HMB in this population and for targeted clinical guidelines and optimized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.